Literature DB >> 6337667

Placebo--the drug of choice in female motor urge incontinence?

H H Meyhoff, T C Gerstenberg, J Nordling.   

Abstract

In a randomised double-blind cross-over trial of 19 females with motor urge incontinence but without bladder suspension defect, the effects of 14 days' treatment with emepronium bromide 200 mg qid, flavoxate chloride 200 mg qid or placebo qid were compared by means of micturition charts, the patients' drug preferences and evaluation of side effects. Placebo was the only drug giving rise to a statistically significant decrease in the frequency of voidings, incontinence and nocturia. Forty-seven per cent of the patients preferred placebo and side effects were less frequent during treatment with this medication. No differences could be demonstrated between the effects of emepronium bromide and flavoxate chloride. Perhaps detrusor instability is not always the main reason for the voiding dysfunction in these patients, in whom the effect of placebo was equal or superior to the effect of "active drugs" and superior to no treatment at all.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6337667     DOI: 10.1111/j.1464-410x.1983.tb07075.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  11 in total

Review 1.  Detrusor instability; day and night time wetting, urinary tract infections.

Authors:  R Fisher; D Frank
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

2.  Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials.

Authors:  Roger R Dmochowski; Victor Nitti; David Staskin; Karl Luber; Rodney Appell; G Willy Davila
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

Review 3.  Urinary incontinence in the elderly. Causes and treatment options.

Authors:  S Z Nasr; J G Ouslander
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

Review 4.  Tolterodine: a review of its use in the treatment of overactive bladder.

Authors:  D Clemett; B Jarvis
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Comparative tolerability of drug therapies used to treat incontinence and enuresis.

Authors:  R G Owens; M M Karram
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

Review 6.  [Overactive bladder--treatment with antimuscarinic agents].

Authors:  K Höfner
Journal:  Urologe A       Date:  2003-05-20       Impact factor: 0.639

7.  [Epidemiology and etiology of overactive bladder].

Authors:  C Hampel; R Gillitzer; S Pahernik; M Hohenfellner; J W Thüroff
Journal:  Urologe A       Date:  2003-04-29       Impact factor: 0.639

Review 8.  Anticholinergic drugs versus other medications for overactive bladder syndrome in adults.

Authors:  C Roxburgh; J Cook; N Dublin
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.

Authors:  Steven E Swift; Paul Siami; Sergio Forero-Schwanhaeuser
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 10.  Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.

Authors:  G Nabi; J D Cody; G Ellis; P Herbison; J Hay-Smith
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.